Filing Flows › Sight Sciences (SGHT) › Recalls, complaints & regulation

Sight Sciences (SGHT): recalls and clinical trials

Sight Sciences (SGHT) beyond its filings: 0 recalls in the last 12 months (1 in five years, 0 Class I); 2 active clinical trials.

Latest recalls

2022-05-04 · FDA device · TearCare version 1.0 SmartHubs

Sight Sciences' latest quarter

Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%, net loss $6.8M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.

Questions

Has Sight Sciences had any recalls?

1 recall on file over five years from the FDA, CPSC and NHTSA; 0 in the last 12 months.

How many clinical trials does Sight Sciences have?

2 active studies on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.